Abstract:Aim: Inflammation plays a critical role in the progression of diabetic nephropathy. Peroxisome proliferator-activated receptor gamma (PPARγ) and its coactivator PPARγ coactivator-1 alpha (PGC-1α) enhance mitochondrial biogenesis and cellular energy metabolism but inhibit inflammation. However, the molecular mechanism through which these two proteins cooperate in the kidney remains unclear. The aim of the present study was to investigate this mechanism. Methods: HK-2 human proximal tubular cells were stimulated by inflammatory factors, the expression of PPARγ and PGC-1α were determined via reverse transcription-quantitative polymerase chain reaction (PCR) and western blotting (WB), and DNA binding capacity was measured by an EMSA. Furthermore, db/db mice were used to establish a diabetic nephropathy model and were administered PPARγ and PGC-1α activators. Kidney injury was evaluated microscopically, and the inflammatory response was assessed via WB, immunohistochemistry and immunofluorescence staining. Besides, HK-2 cells were stimulated by high glucose and inflammatory factors with and without ZLN005 treatment, the expression of PPARγ, PGC-1α, p-p65 and p65 were determined via qPCR and WB. Results: Our results revealed that both TNF-α and IL-1β significantly decreased PPARγ and PGC-1 expression in vitro. Cytokines obviously decreased PPARγ DNA binding capacity. Moreover, we detected rapid activation of the NF-κB pathway in the presence of TNF-α or IL-1β. PPARγ and PGC-1α activators effectively protected against diabetic nephropathy and suppressed NF-κB expression both in db/db mice and HK-2 cells. Conclusion: PPARγ and its coactivator PGC-1α actively participate in protecting against renal inflammation by regulating the NF-κB pathway, which highlights their potential as therapeutic targets for renal diseases.

Role of PPARgamma in Renoprotection in Type 2 Diabetes: Molecular Mechanisms and Therapeutic Potential.

PPARγ As a Therapeutic Target in Diabetic Nephropathy and Other Renal Diseases

Emerging Protective Actions of PGC-1α in Diabetic Nephropathy

New Insights into the PPAR Γ Agonists for the Treatment of Diabetic Nephropathy.

Effects of thiazolidinediones on protection of the kidney

PPAR gamma and PGC-1alpha activators protect against diabetic nephropathy by suppressing the inflammation and NF-kappaB activation

PPARγ and PGC-1α activators protect against diabetic nephropathy by suppressing the inflammation and NF-κB activation

Peroxisome Proliferator-Activated Receptor Alpha Stimulation Preserves Renal Tight Junction Components in a Rat Model of Early-Stage Diabetic Nephropathy

PGC1-α in diabetic kidney disease: unraveling renoprotection and molecular mechanisms

Peroxisome proliferator-activated receptors and renal diseases.

Effects of PPARγ Agonists Against Vascular and Renal Dysfunction

P2Y2R contributes to the development of diabetic nephropathy by inhibiting autophagy response

Pharmacological Activation of PPAR Gamma Ameliorates Vascular Endothelial Insulin Resistance Via a Non-Canonical PPAR Gamma-Dependent Nuclear Factor-Kappa B Trans-Repression Pathway.

The Role of PPARγ Gene Polymorphisms, Gut Microbiota in Type 2 Diabetes: Current Progress and Future Prospects

Resveratrol Attenuates Early Diabetic Nephropathy by Down-Regulating Glutathione S-Transferases Mu in Diabetic Rats

PP2 Ameliorates Renal Fibrosis by Regulating the NF-κB/COX-2 and PPARγ/UCP2 Pathway in Diabetic Mice

Protective Effect of Peroxisome Proliferator Activated Receptor Gamma Agonists on Diabetic and Non‐diabetic Renal Diseases

Effects of PPARγ on Hypertension, Atherosclerosis, and Chronic Kidney Disease.

Protective Role of PGC-1α in Diabetic Nephropathy is Associated with the Inhibition of ROS Through Mitochondrial Dynamic Remodeling.

Adiponectin and Its Receptors in Diabetic Kidney Disease: Molecular Mechanisms and Clinical Potential

PPAR-γ Signaling in Podocyte Injury